Auregen BioTherapeutics

Executive Summary

Auregen BioTherapeutics is a private, Cambridge-based biotechnology company founded in 2020, dedicated to developing gene therapies for rare genetic diseases through innovative delivery platforms within the tissue engineering sector. The company's approach leverages novel vectors and tissue-specific targeting to address conditions with high unmet medical need, positioning it as a potential leader in next-generation gene therapy. Since its inception, Auregen has focused on advancing its lead candidate toward clinical development, leveraging its proprietary platform to enhance durability and safety. While the company remains in early stages, its scientific foundation and strategic positioning in a rapidly evolving field suggest significant potential for long-term value creation, contingent on successful execution of preclinical and clinical milestones.

Upcoming Catalysts (preview)

• Q3 2026IND Filing for Lead Gene Therapy Candidate70% success
• Q2 2026Presentation of Preclinical Efficacy Data at Major Conference80% success
• Q4 2026Strategic Partnership or Licensing Deal for Delivery Platform50% success